Gossamer Bio Statistics
Gossamer Bio (4GB0) Stock Statistics & Valuation Metrics
Total Valuation
Gossamer Bio has a market cap or net worth of EUR 62.12M. The enterprise value is EUR 67.04M.
- Market Cap
- EUR 62.12M
- Enterprise Value
- EUR 67.04M
Share Statistics
Gossamer Bio has 6,110,584 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 6,110,584
- Owned by Insiders
- 1.86%
- Owned by Institutions
- 45.21%
Financial Efficiency
Gossamer Bio’s return on equity (ROE) is 1.39 and return on invested capital (ROIC) is -148.67%.
- Return on Equity (ROE)
- 1.39
- Return on Assets (ROA)
- -0.99
- Return on Invested Capital (ROIC)
- -148.67%
- Return on Capital Employed (ROCE)
- -1.50
- Revenue Per Employee
- 299.20K
- Profits Per Employee
- -1.05M
- Employee Count
- 162
- Asset Turnover
- 0.28
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Gossamer Bio is -0.33. Gossamer Bio’s PEG ratio is -0.01.
- PE Ratio
- -0.33
- PS Ratio
- 0.91
- PB Ratio
- -0.62
- Price to FCF
- -0.46
- Price to Operating Cash Flow
- -0.49
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Gossamer Bio had revenue of 48.47M and earned -170.37M in profits. Earnings per share was -59.64.
- Revenue
- 48.47M
- Gross Profit
- 47.47M
- Operating Income
- -163.25M
- Pretax Income
- -170.46M
- Net Income
- -170.37M
- EBITDA
- -158.47M
- Earnings Per Share (EPS)
- -59.64
Cash Flow
In the last 12 months, operating cash flow was -156.04M and capital expenditures 0, giving a free cash flow of -156.04M billion.
- Operating Cash Flow
- -156.04M
- Free Cash Flow
- -156.04M
- Free Cash Flow per Share
- -23.90
Dividends & Yields
Gossamer Bio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -223.02%
- Earnings Yield
- -167.28%
Stock Price Statistics
- Beta
- 0.09
- 52-Week Price Change
- -94.71%
- 50-Day Moving Average
- 9.46
- 200-Day Moving Average
- 26.32
- Relative Strength Index (RSI)
- 51.98
- Average Volume (3m)
- 60
Important Dates
Gossamer Bio upcoming earnings date is Mar 12, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 12, 2027
- Ex-Dividend Date
- ―
Financial Position
Gossamer Bio as a current ratio of 2.64, with Debt / Equity ratio of -165.29%
- Current Ratio
- 2.64
- Quick Ratio
- 2.64
- Debt to Market Cap
- 0.28
- Net Debt to EBITDA
- -1.04
- Interest Coverage Ratio
- -14.86
Taxes
In the past 12 months, Gossamer Bio has paid -88.00K in taxes.
- Income Tax
- -88.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Gossamer Bio EV to EBITDA ratio is -0.29, with an EV/FCF ratio of -0.38.
- EV to Sales
- 0.76
- EV to EBITDA
- -0.29
- EV to Free Cash Flow
- -0.38
- EV to Operating Cash Flow
- -0.38
Balance Sheet
Gossamer Bio has EUR 51.19M in cash and marketable securities with EUR 40.85M in debt, giving a net cash position of EUR 10.34M billion.
- Cash & Marketable Securities
- EUR 51.19M
- Total Debt
- EUR 40.85M
- Net Cash
- EUR 10.34M
- Net Cash Per Share
- EUR 1.69
- Tangible Book Value Per Share
- -EUR 18.80
Margins
Gross margin is 99.70%, with operating margin of -139.99%, and net profit margin of -159.49%.
- Gross Margin
- 99.70%
- Operating Margin
- -139.99%
- Pretax Margin
- -159.60%
- Net Profit Margin
- -159.49%
- EBITDA Margin
- -261.45%
- EBIT Margin
- -262.65%
Analyst Forecast
The average price target for Gossamer Bio is EUR 98.49, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 98.49
- Price Target Upside
- 1014.12% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 70.52%
- EPS Growth Forecast
- 38.03%
Scores
- Smart Score
- 5
- AI Score
- ―
